% | $
Quotes you view appear here for quick access.

Array BioPharma Inc. Message Board

  • dcaf7 dcaf7 Nov 8, 2013 9:02 AM Flag

    ASH abstract on selutenib in pediatric ALL

    It seems like a new indication for the drug.
    823 RAS Pathway Mutations Are Highly Prevalent In Relapsed Childhood Acute Lymphoblastic Leukaemia, Are Frequently Relapse-Drivers and Confer Sensitivity To MEK Inhibition
    From the abstract:
    In summary, we show that RAS pathway mutations are a common genetic abnormality in relapsed ALL and are associated with high risk features and are often relapse-drivers. Targeted MEK inhibition with selumetinib shows excellent activity in RAS mutated ALL both in vitro and in vivo and may offer clinical benefit for a substantial proportion of children with relapsed ALL. Given our findings, clinical trials of selumetinib in RAS pathway positive relapsed patients are warranted.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
3.74-0.03(-0.80%)Jul 29 4:00 PMEDT